SCHEMBL20629290

SCHEMBL20629290

CN1CC(=O)N2CCc3c(c4cc(OCCN5CCOCC5)ccc4n3Cc3ccc(C(=O)O)cc3)C2C1=O

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 14/20 0.58
▸ HDAC2 Q92769 12/20 0.58
▸ HDAC8 Q9BY41 10/20 0.58
▸ HDAC3 O15379 7/20 0.51
▸ HDAC1 Q13547 7/20 0.51
▸ HDAC10 Q969S8 1/20 0.51
▸ GAA P10253 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ ESR1 P03372 1/20 0.40
▸ ESR2 Q92731 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20635578 0.94 HDAC6 (0.58) HDAC6HDAC2HDAC8HDAC3HDAC1
SCHEMBL20629485 0.92 HDAC6 (0.69) HDAC6HDAC2HDAC8HDAC3HDAC1
Hydrochloric Acid SCHEMBL20605308 0.92 HDAC6 (0.70) HDAC6HDAC2HDAC8HDAC3HDAC1
SCHEMBL20629487 0.91 HDAC2 (0.54) HDAC6HDAC2HDAC8HDAC3HDAC1
SCHEMBL20629461 0.91 HDAC6 (0.63) HDAC6HDAC2HDAC8HDAC3HDAC1
SCHEMBL22487712 0.90 HDAC2 (0.55) HDAC6HDAC2HDAC8HDAC3HDAC1
SCHEMBL20629287 0.86 HDAC6 (0.56) HDAC6HDAC2HDAC8HDAC3HDAC1
SCHEMBL20635482 0.86 HDAC6 (0.58) HDAC6HDAC2HDAC8HDAC3HDAC1
SCHEMBL20629341 0.85 HDAC6 (0.60) HDAC6HDAC2HDAC8HDAC3HDAC1
SCHEMBL20605315 0.81 HDAC6 (0.62) HDAC6HDAC2HDAC8HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11198694-B2 HDAC6 inhibitors, with improved solubility and their uses UNIVERSITÄT REGENSBURG (DE) 2021-12-14 — — US disclosed
US-20200308174-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2020-10-01 — — US disclosed
WO-2019007836-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2019-01-10 — — WO disclosed
EP-3424925-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES Universität Regensburg (DE) 2019-01-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11198694-B2 HDAC6 inhibitors, with improved solubility and their uses HDAC6, HDAC1, HDAC5 HDAC6 1/4885HDAC2 4/4885HDAC8 6/4885
US-20200308174-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES HDAC6, HDAC1, HDAC2 HDAC6 1/4885HDAC2 3/4885HDAC8 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback